Recent advancements in systems biology have been propelled by the increasing power of omics technologies—spanning genomics, transcriptomics, proteomics, ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer ...
Refeyn, developer of pioneering mass photometry technology, expands its global adoption across contract research ...